厄洛替尼治疗晚期非小细胞肺癌并发皮肤不良反应的护理对策

Nursing measures of adverse skin reactions resulting from Erlotinib for treating non-small cell lung cancer(NSCLC)

目的:针对厄洛替尼小分子靶向药引起的皮肤不良反应,研究控制及护理对策。方法:按照国际统一分级标准,观察皮疹特点并评估,采用全身用药与局部用药相结合,中西医治疗相结合,多种护理方法并用等措施预防和控制皮肤损害。结果:多数病人的皮肤不良反应得以减轻或治愈,能较好的控制皮疹的周期性发作。结论:系统皮肤护理和适当的药物治疗有助于改善小分子靶向药引起的皮肤不良反应,配合完成抗肿瘤治疗。

Objective： To investigate the nursing measures of controlling adverse skin reactions resulting from Erlotinib for treating NSCLC.Methods： 31 NSCLC patients with adverse skin reactions were categorized using a national scale paying particular attention to rash characteristics.Different methods of treatments and nursing to control and prevention skin lesion were utilized including systemic comprehensive therapy combining with local drug,therapy of western medicine,and traditional chinese medicine.Results： Some patients were successfully treated,adverse skin reactions of other patients were reduced.Correct nursing care also reduced the occurrence of periodic rash.Conclusion： Systematic nursing care and drugs therapy.can successfully prevent and treat adverse skin reactions resulting from tyrosine kinase inhibitors（TKIs） and help to anti-cancer treatment of NSCLC patients.